RPRX: Early target achievement and global expansion fuel strong growth and innovation in royalty funding

Surpassing its five-year capital deployment target early, the firm is leveraging new opportunities in Big Pharma and China, driving robust growth and innovation in R&D co-funding and synthetic royalties. Enhanced by a proprietary data platform and AI, it expects double-digit top-line growth through…